The Centre on Wednesday took steps to accelerate domestic vaccine production. Mumbai-based Haffkine Biopharma will produce 22.8 crore doses per annum of Covaxin under technology transfer arrangement with Bharat Biotech.
With the aim of vaccinating the entire eligible population at the earliest, domestic vaccine production is being steadily ramped up in the country with help from the Centre. As part of this initiative, three public enterprises are being supporte
The Centre on Wednesday took steps to accelerate domestic vaccine production. Mumbai-based Haffkine Biopharma will produce 22.8 crore doses per annum of Covaxin under technology transfer arrangement with Bharat Biotech.With the aim of .
2021-06-02 11:35:32 GMT2021-06-02 19:35:32(Beijing Time) Xinhua English
MUMBAI, June 2 (Xinhua) India s state-owned Haffkine BioPharma has entered into a technology transfer pact with the country s vaccine producer Bharat Biotech to produce 228 million doses per annum of COVID-19 vaccine, the government s Press Information Bureau said Wednesday.
The Mumbai-based Haffkine BioPharma will produce these vaccines at its Parel complex located in the central part of the city.
Bharat Biotech has developed India s indigenous COVID-19 vaccine in collaboration with two state-owned agencies - Indian Council of Medical Research and National Institute of Virology using whole-virion inactivated vero cell derived platform technology under the brand name Covaxin.